News
Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
2don MSNOpinion
Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...
Novo Nordisk on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut ...
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback